SOURCE-LINKED STUDY SUMMARY
Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.
Abstract summarizedQuality not appraised
- What was studied
- This randomized trial tested whether tesamorelin, a stabilized GHRH analog, improved cognition in older adults with or without mild cognitive impairment.
- Who / model studied
- The trial enrolled 152 adults aged 55–87, including 66 with mild cognitive impairment; 137 completed the study.
- Studied dose & schedule
- Participants self-injected tesamorelin 1 mg subcutaneously each day or placebo 30 minutes before bedtime for 20 weeks, followed by a 10-week washout.
- What the study found
- Intent-to-treat analysis favored tesamorelin for overall cognition (P=.03), driven by executive-function improvement (P=.005); verbal-memory benefit remained a trend.
- Limitations & context
- The intervention lasted 20 weeks. Mild adverse events occurred in 68% receiving GHRH and 36% receiving placebo; longer trials were recommended.
Read summary source ↗ · Prepared 10/6/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1001/archneurol.2012.1970